Reprogramming cell fates towards novel cancer immunotherapies

Eva Hin Wa Leung; Kenneth Joves; Aydolun Petenkaya; Georgina Barham; Thomas G Henderson; Jie Liang; Constantinos Chronis

doi:10.1016/j.coph.2022.102312

Reprogramming cell fates towards novel cancer immunotherapies

Curr Opin Pharmacol. 2022 Dec:67:102312. doi: 10.1016/j.coph.2022.102312. Epub 2022 Nov 3.

Authors

Eva Hin Wa Leung¹, Kenneth Joves¹, Aydolun Petenkaya², Georgina Barham¹, Thomas G Henderson¹, Jie Liang³, Constantinos Chronis⁴

Affiliations

¹ Department of Biochemistry and Molecular Genetics, UIC, USA.
² Department of Biochemistry and Molecular Genetics, UIC, USA; Richard and Loan Hill Dept of Biomedical Engineering, UIC, USA.
³ Richard and Loan Hill Dept of Biomedical Engineering, UIC, USA.
⁴ Department of Biochemistry and Molecular Genetics, UIC, USA; Richard and Loan Hill Dept of Biomedical Engineering, UIC, USA. Electronic address: chronis@uic.edu.

PMID: 36335715
DOI: 10.1016/j.coph.2022.102312

Abstract

Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.

Publication types

Review

MeSH terms

Humans
Immunotherapy* / methods
Neoplasms* / therapy